International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com),
a California-based stem cell therapeutics company, today announced that
the Company will present at the LD Micro Conference on Tuesday, April 29th
at 8:00am PDT. Chairman and Chief Executive Officer, Kenneth Aldrich,
will represent the company. The conference will be held at the Omni Los
Angeles Hotel in Los Angeles, California.
LD MICRO is a by-invitation only newsletter firm that focuses on finding
undervalued companies in the micro-cap space. Since 2002, the firm has
published an annual list of recommended stocks as well as comprehensive
reports on selected names throughout the year.
"We are delighted that International Stem Cell is attending our event.
We think it is one of the most exciting companies in Southern
California," said Chris Lahiji, President of LD MICRO.
For information on the list of presenting companies or to register for
the event, please visit http://ldmicro.com
or call 310-862-4512.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists have created the first Parthenogenetic homozygous stem
cell line (phSC-Hhom-4) that can be a source of therapeutic cells
that will not be immune rejected after transplantation into millions of
individuals of differing sexes, ages and racial groups. These
advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by
eliminating the need to use or destroy fertilized embryos. ISCO also
produces and markets specialized cells and growth media worldwide for
therapeutic research through its subsidiary Lifeline Cell Technology.
For more information, visit the ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 Forward-Looking Statements Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update these forward-looking statements. KEYWORDS: Stem Cells, Biotechnology, Parthenogenesis |